NCT06281847View on ClinicalTrials.gov

An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

143

Participants

Timeline

Start Date

December 31, 2025

Primary Completion Date

July 31, 2027

Study Completion Date

August 31, 2041

Conditions
Acute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia Refractory
Interventions
GENETIC

CCTx-001

Frozen CAR T-cells suspensions in media containing dimethyl sulfoxide (DMSO)

Trial Locations (6)

Unknown

Besançon Regional and University Hospital, Besançon

Hospital Saint Louis, Paris

Ludwig-Maximilians University of Munich, Munich

University Hospital Ulm, Ulm

Vall d'Hebron University Hospital, Barcelona

Karolinska University Hospital, Stockholm

Sponsors

Lead Sponsor

Advesya SAS
All Listed Sponsors
lead

Advesya SAS

INDUSTRY

NCT06281847 - An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia | Biotech Hunter | Biotech Hunter